Atlas Trials

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

Clinical trial NCT00444912 · COMPLETED

Trial details

NCT number
NCT00444912
Sponsor
Genzyme, a Sanofi Company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Hodgkin LymphomaHodgkin Disease
Start date
2006-02-01
Primary completion
2009-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.